Cargando…
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
Breast cancer (BC) is the most common women cancer and cause of cancer death. Despite decades of scientific progress in BC treatments, the clinical benefit of new drugs is modest in several cases. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pa...
Autores principales: | Cerma, Krisida, Piacentini, Federico, Moscetti, Luca, Barbolini, Monica, Canino, Fabio, Tornincasa, Antonio, Caggia, Federica, Cerri, Sara, Molinaro, Alessia, Dominici, Massimo, Omarini, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855880/ https://www.ncbi.nlm.nih.gov/pubmed/36672617 http://dx.doi.org/10.3390/biomedicines11010109 |
Ejemplares similares
-
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022) -
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022) -
Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020) -
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021) -
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)